CNS PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.23 USD | -7.85% |
|
-38.12% | -96.47% |
| 14/06 | CNS Pharmaceuticals, Inc. announced that it expects to receive $1.3725 million in funding | CI |
| 10/06 | Sector Update: Health Care Stocks Advance Late Afternoon | MT |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 6.67M 557M |
|---|---|---|---|---|---|
| Net income 2022 | -15M -1.25B | Net income 2023 | -18M -1.5B | EV / Sales 2022 | - |
| Net cash position 2022 | 9.65M 806M | Net cash position 2023 | 248K 20.72M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.21
x | P/E ratio 2023 |
-0.25
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 91.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on CNS Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | -7.85% | ||
| 1 week | -38.12% | ||
| Current month | -79.28% | ||
| 1 month | -79.26% | ||
| 3 months | -87.62% | ||
| 6 months | -95.47% | ||
| Current year | -96.47% |
1 week
2.18
8.28
1 month
2.1816.00
Current year
2.1865.00
1 year
2.18137.50
3 years
2.184 020.00
5 years
2.188 534.86
10 years
2.188 534.86
| Managers | Title | Age | Since |
|---|---|---|---|
John Climaco
CEO | Chief Executive Officer | 55 | 01/17/01 |
| Director of Finance/CFO | 45 | 13/19/13 | |
Sandra Silberman
CTO | Chief Tech/Sci/R&D Officer | 69 | 01/17/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Picker
CTO | Chief Tech/Sci/R&D Officer | 78 | 01/18/01 |
John Climaco
CEO | Chief Executive Officer | 55 | 01/17/01 |
Faith Charles
CHM | Chairman | 62 | 03/23/03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/24/20 | 2.24 | -7.44% | 67 980 |
| 18/24/18 | 2.42 | -16.55% | 193,542 |
| 17/24/17 | 2.9 | +3.94% | 789,324 |
| 14/24/14 | 2.79 | -22.93% | 9,926,883 |
| 13/24/13 | 3.62 | +15.65% | 117,265 |
Delayed Quote Nasdaq, June 20, 2024 at 08:05 pm IST
More quotes
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.
Calendar
12/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -96.47% | 574K | |
| +35.59% | 51.07B | |
| -8.20% | 38.78B | |
| +35.03% | 38.61B | |
| -8.98% | 27.32B | |
| +11.63% | 26.35B | |
| -19.12% | 19.46B | |
| +40.45% | 13.58B | |
| +30.25% | 12.46B | |
| -4.11% | 11.75B |
- Stock Market
- Equities
- CNSP Stock
